Skip to content

MAINMAIN

About
Our Team
Foundation
Investments
VENTURE FUND
Contact Us

MAINMAIN

About
Our Team
Foundation
Investments

VENTURE FUND VENTURE FUND

INVESTOR FINANCIALS
SHARE PRICE CENTER
Results Center
Investor Bulletin
RNS & Inside Information
Fund News
Calendar
INVESTOR INFORMATION
DOCUMENT LIBRARY
INQUIRIES

Our Investments

We are full life cycle investors supporting scientists and entrepreneurs at any stage where we identify opportunity, from academic programs in need of industry sponsorship all the way to mature publicly traded companies.

Select Investments

All Investments
RTW Venture Fund LTD Investments

Armo BioSciences is an immuno-oncology company with a pipeline of novel interleukins for cancer.

Athira is a clinical-stage company developing innovative first-in-class regenerative therapies with the potential to restore brain function.

Attune is developing small molecules for hereditary angioedema.

AveXis is a Dallas-based company developing gene therapy for spinal muscular atrophy, an often progressive and disabling muscle wasting disease.

Avidity Biosciences is a privately-held biotech company pioneering Antibody Oligonucleotide Conjugates (AOC™).

Beta Bionics is the developer of the iLet®, a revolutionary bionic pancreas driven by machine-learning artificial intelligence to autonomously control blood sugar.

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell.

Dermtech has developed a non-invasive adhesive patch for the diagnosis of metastatic melanoma.

Encoded is developing life-changing therapeutics for severe genetic disorders that are not addressable with existing gene therapy approaches.

Establishment Labs is developing safer next-generation cosmetic implants.

Frequency Therapeutics develops small molecule drugs that activate progenitor cells to restore hair cells lost in noise-induced hearing loss.

Immunocore is a London-based company with an immuno-oncology platform technology called ImmTACs. ImmTACs enable the potent targeting of intracellular cancer antigens with controlled pharmacology.

Immunovant is developing a FCRN antibody with broad potential in antibody-mediated autoimmune disease.

iTeos Therapeutics is designing and developing next generation immunotherapies targeting two key resistance pathways to checkpoint therapy: the adenosine pathway and regulatory T cells (Tregs).

LaJolla Pharmaceutical is a California biotech focused on endogenous peptides and therapies for rare diseases.

Landos Biopharma is developing first-in-class oral therapeutics for autoimmune diseases including inflammatory bowel disease (IBD).

Milestone is a late-stage biopharmaceutical company developing a drug intended to provide outpatient treatment of paroxysmal supraventricular tachycardia (PSVT).

NiKang is a preclinical stage biotech company discovering and developing innovative small molecule oncology medicines.

Odonate Therapeutics is developing a novel oral taxane for breast cancer.

Orchard Therapeutics is a biotechnology company dedicated to bringing transformative gene therapies to patients with serious and life-threatening orphan diseases.

Pulmonx is a commercial-stage medical technology company that provides a minimally-invasive treatment for patients with severe emphysema.

Orchestra Biomed is the developer of Virtue SEB, a sirolimus eluting balloon for treatment of coronary and peripheral arterial disease.

ReGenX is the most broadly licensed AAV capsid technology platform in gene therapy. ReGenX’s own pipeline is focused on metabolic, CNS, and retinal diseases.

Rocket Pharma brings hope and relief to patients with undertreated rare diseases through the development and commercialization of curative first-in-class gene-modified cell therapies.

Solid Biosciences is dedicated to developing therapies for Duchenne Muscular Dystrophy, a disease characterized by progressive muscular weakness in boys.

Stoke is developing antisense oligos that target RNA splicing to increase gene expression for the treatment of severe genetic diseases, including Dravet Syndrome.

Tarsus is focused on the development and commercialization of first-in-class therapeutic candidates to address large market opportunities initially in ophthalmic conditions such as Demodex blepharitis

Avidity Biosciences is a privately-held biotech company pioneering Antibody Oligonucleotide Conjugates (AOC™).

Athira is a clinical-stage company developing innovative first-in-class regenerative therapies with the potential to restore brain function.

Beta Bionics is the developer of the iLet®, a revolutionary bionic pancreas driven by machine-learning artificial intelligence to autonomously control blood sugar.

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell.

Frequency Therapeutics develops small molecule drugs that activate progenitor cells to restore hair cells lost in noise-induced hearing loss.

Immunocore is a London-based company with an immuno-oncology platform technology called ImmTACs. ImmTACs enable the potent targeting of intracellular cancer antigens with controlled pharmacology.

iTeos Therapeutics is designing and developing next generation immunotherapies targeting two key resistance pathways to checkpoint therapy: the adenosine pathway and regulatory T cells (Tregs).

Landos Biopharma is developing first-in-class oral therapeutics for autoimmune diseases including inflammatory bowel disease (IBD).

NiKang is a preclinical stage biotech company discovering and developing innovative small molecule oncology medicines.

Orchestra Biomed is the developer of Virtue SEB, a sirolimus eluting balloon for treatment of coronary and peripheral arterial disease.

Pulmonx is a commercial-stage medical technology company that provides a minimally-invasive treatment for patients with severe emphysema.

Rocket Pharma brings hope and relief to patients with undertreated rare diseases through the development and commercialization of curative first-in-class gene-modified cell therapies.

Tarsus is focused on the development and commercialization of first-in-class therapeutic candidates to address large market opportunities initially in ophthalmic conditions such as Demodex blepharitis

Let's Talk.
Contact us to learn more about RTW’s expertise, insight and experience in identifying and working with companies focused in areas of breakthrough innovation.
Name
First Last
Company / Organization
Email*
How can we be of assistance?
CAPTCHA
Comments
This field is for validation purposes and should be left unchanged.

RTW INVESTMENTS, LP
40 10th Avenue, Floor 7
New York, NY 10014

Phone: (646) 597-6980
Fax: (646) 597-6998

COMPANIES
companies@rtwfunds.com

HR INQUIRIES
hr@rtwfunds.com

INTERNSHIP OPPORTUNITIES
intern@rtwfunds.com

Copyright © 2020 RTW Investments, LP. All rights reserved.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settings ACCEPT

Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

Access our Annual Results 2019 Presentation Recording

Name*
First Last
Company*
Email*
Enter Email Confirm Email
Email
This field is for validation purposes and should be left unchanged.